Full Coverage

ThromboGenics NV - Q3 2009 Business Update

                   
redorbit.com
Nov 4, 2009
 
Story Timeline:  23 days

LEUVEN, Belgium, November 4 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a... [read full story]                    

powered by
Add Comment
Latest article on this story:

ThromboGenics NV - Q3 2009 Business Update

 smartbrief.com Nov 4, 2009
First article on this story:

ThromboGenics NV - Q3 2009 Business Update

 prnewswire.com Nov 4, 2009
Selected publications with coverage of this story:
redorbit.com prnewswire.com earthtimes.org smartbrief.com finanznachrichten.de
RELATED
Found 4 documents:
                   

ThromboGenics NV - Q3 2009 Business Update

smartbrief.com
Nov 4, 2009
 

LEUVEN, Belgium, November 4 /PRNewswire-FirstCall/ -- The second Phase III study with microplasmin, TG-MV-007, which is recruiting 320 patients in Europe and the US, is progressing well and we expect complete enrolment within...

powered by
                   

ThromboGenics NV - Q3 2009 Business Update

finanznachrichten.de
Nov 4, 2009
 

LEUVEN, Belgium, November 4 /PRNewswire-FirstCall/ -- The second Phase III study with microplasmin, TG-MV-007, which is recruiting 320 patients in Europe and the US, is progressing well and we expect complete enrolment within...

powered by
                   

ThromboGenics NV - Q3 2009 Business Update

earthtimes.org
Nov 4, 2009
 

LEUVEN, Belgium, November 4 -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the...

powered by
                   

ThromboGenics NV - Q3 2009 Business Update

prnewswire.com
Nov 4, 2009
 

LEUVEN, Belgium, November 4 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a...

powered by